A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours

Second-line treatments recommended by the National Cancer Center Network to manage advanced-stage gastrointestinal stromal tumours (GIST) were evaluated to determine the cost and cost-effectiveness of each intervention in the Mexican insurance system, the Instituto Mexicano del Seguro Social (IMSS)....

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras-Hernández, I, Mould-Quevedo, J F, Silva, A, Salinas-Escudero, G, Villasís-Keever, M A, Granados-García, V, Dávila-Loaiza, G, Petersen, J A, Garduño-Espinosa, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410103/
https://www.ncbi.nlm.nih.gov/pubmed/18506179
http://dx.doi.org/10.1038/sj.bjc.6604367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410103/
https://www.ncbi.nlm.nih.gov/pubmed/18506179
http://dx.doi.org/10.1038/sj.bjc.6604367

Ejemplares similares